Description

Bulevirtide, also known as Myrcludex B, is a synthetic linear lipopeptide composed of 47 amino acids. As a potent NTCP (sodium taurocholate co-transporting polypeptide) inhibitor, Bulevirtide specifically prevents hepatitis B virus (HBV) and hepatitis D virus (HDV) from entering hepatocytes by blocking their receptor-mediated entry. It also shows transcriptional suppression of HBV, making it a powerful tool in virology and liver disease research.

Produced under GMP-compliant conditions, Bulevirtide is ideal for laboratories conducting high-standard research on viral infections and hepatocellular function.

This product is intended strictly for laboratory research use only. It is not for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

Bulevirtide targets the NTCP receptor on hepatocytes, blocking the binding and entry of HBV and HDV into liver cells. This NTCP antagonism also leads to transcriptional suppression of HBV. It is a key molecule in developing antiviral strategies against chronic liver infections.

Research Applications:

• Hepatitis B (HBV) entry inhibition

• Hepatitis D (HDV) infection studies

• Viral transcription regulation

• NTCP receptor mechanism studies

• Compensated cirrhosis models

• Liver disease and hepatocyte-targeting drug screening

  

Things to note

In laboratory models, Bulevirtide has been observed to:

• Alter hepatocyte uptake of bile acids (via NTCP inhibition)

• Modulate liver cell receptor expression

• Suppress HBV replication in vitro
  These findings are strictly relevant to controlled lab conditions and not for clinical interpretation.

Disclaimer

This product is manufactured in a GMP-compliant facility and intended strictly for research purposes only. It is not approved for human or animal use, clinical diagnosis, or therapeutic application. Use in academic or industrial labs only.